SCHEMBL5120116

SCHEMBL5120116

Cc1cccc(-c2nc3ccc(Cl)nn3c2-c2ccnc(Nc3ccccc3C)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 12/20 0.50
MAPK12 P53778 12/20 0.50
MAPK11 Q15759 12/20 0.50
MAPK14 Q16539 12/20 0.50
MAPK10 P53779 1/20 0.49
GAA P10253 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 1/20 0.39
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
RIPK3 Q9Y572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125059 0.89 MAPK14 (0.46) MAPK13MAPK12MAPK11MAPK14MAPK10
SCHEMBL5120315 0.86 MAPK14 (0.67) MAPK13MAPK12MAPK11MAPK14MAPK10
SCHEMBL5118834 0.82 MAPK14 (0.47) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL5126526 0.82 MAPK14 (0.60) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5116673 0.81 MAPK14 (0.46) MAPK13MAPK12MAPK11MAPK14AKT1
SCHEMBL5119031 0.80 MAPK14 (0.53) MAPK13MAPK12MAPK11MAPK14MAPK10
SCHEMBL5126675 0.79 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14MAPK10
SCHEMBL5127049 0.77 MAPK14 (0.42) MAPK13MAPK12MAPK11MAPK14AKT1
SCHEMBL5126371 0.76 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5127350 0.75 MAPK13 (0.63) MAPK13MAPK12MAPK11MAPK14MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK13 1/4885MAPK12 9/4885MAPK11 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.